|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
Experimental Genetics Group
Neurobiol Dis. 2002 Feb;9(1):38-48. Nuydens R1, Van Den Kieboom G1, Nolten C1, Verhulst C1, Van Osta P1, Spittaels K2, Van den Haute C2, De Feyter E1, Geerts H1, Van Leuven F2. 1CNS Discovery Research, Janssen Research Foundation, Beerse, Belgium. 2Experimental Genetics Group, CME-KU Leuven, Leuven, Belgium. Coexpression of constitutively active GSK-3beta[S9A] rescued the axonal pathology induced by overexpression of human tau in transgenic mice (Spittaels et al., (2000) J. Biol. Chem. 275, 41340-41349). We isolated dorsal root ganglion (DRG) neuronal cultures from adult tau4R- and tau4R x GSK-3beta-transgenic mice to define the mechanisms at the cellular and subcellular level. DRG from tau4R-transgenics showed a reduced sprouting capacity while density and stability of microtubules in the axonal processes were significantly increased. Video-enhanced contrast microscopy demonstrated a dramatic inhibition of fast axonal transport. Coexpression of GSK-3beta increased tau phosphorylation and reversed the effects on microtubule stability and saltatory motion. In DRG from GSK-3beta single transgenics, increased tau phosphorylation was evident without any major effects on microtubule stability or axonal transport. These observations support the hypothesis that excess tau competed with motor-proteins for binding to microtubules and/or that a rigid microtubular system inhibits axonal transport.  FULL TEXT |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
Copyright © Katholieke Universiteit Leuven | Comments on the content: Fred Van Leuven Production:Annick Vogels| Most recent update: October 21, 2009 | Disclaimer URL: http://med.kuleuven.be/legtegg/ |
